BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32054412)

  • 1. Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study).
    Hizal M; Sendur MA; Yasar HA; Bir Yucel K; Arslan C; Ucar G; Karakaya S; Taban H; Kucukarda A; Erturk I; Bilgin B; Yıldırım N; Demirci U; Kılıckap S; Cicin I; Karadurmus N; Yalcin B; Ürün Y
    J Oncol Pharm Pract; 2020 Oct; 26(7):1583-1589. PubMed ID: 32054412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis.
    Chang X; Zhang F; Liu T; Wang W; Guo H
    Int Urol Nephrol; 2017 Jun; 49(6):967-974. PubMed ID: 28247169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model.
    Chrom P; Stec R; Bodnar L; Szczylik C
    Cancer Res Treat; 2018 Jan; 50(1):103-110. PubMed ID: 28253564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes.
    Albisinni S; Pretot D; Al Hajj Obeid W; Aoun F; Quackels T; Peltier A; Roumeguère T
    Prog Urol; 2019; 29(8-9):423-431. PubMed ID: 31196826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prognostic value of preoperative neutrophil-to-lymphocyte ratio in patients with non-metastatic renal cell carcinoma].
    Chaker K; Ouanes Y; Dali KM; Bibi M; Messaoudi Y; Mosbehi B; Abid K; Sellami A; Ben Rhouma S; Nouira Y
    Prog Urol; 2022 Jul; 32(8-9):585-592. PubMed ID: 35606294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The neutrophil-to-lymphocyte ratio makes the Heng risk model improve better the prediction of overall survival in metastatic renal cell cancer patients.
    Kim SH; Kwon WA; Kim S; Joung JY; Seo HK; Lee KH; Chung J
    Jpn J Clin Oncol; 2018 Sep; 48(9):835-840. PubMed ID: 30053128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emphasis of neutrophil-to-lymphocyte ratio in non-metastatic renal cell carcinoma.
    Ceylan C; Camtosun A; Doluoglu OG; Tasdemir S; Keles I; Aglamis E; Tatar CA
    Urologia; 2014; 81(1):51-6. PubMed ID: 24474536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
    Gunduz S; Mutlu H; Uysal M; Coskun HS; Bozcuk H
    Asian Pac J Cancer Prev; 2014; 15(8):3801-4. PubMed ID: 24870797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy.
    Tjokrowidjaja A; Goldstein D; Hudson HM; Lord SJ; Gebski V; Clarke S; de Souza P; Motzer RJ; Lee CK
    Acta Oncol; 2020 Jan; 59(1):20-27. PubMed ID: 31462137
    [No Abstract]   [Full Text] [Related]  

  • 10. External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model.
    Chrom P; Zolnierek J; Bodnar L; Stec R; Szczylik C
    Int J Clin Oncol; 2019 May; 24(5):526-532. PubMed ID: 30604160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma.
    de Martino M; Pantuck AJ; Hofbauer S; Waldert M; Shariat SF; Belldegrun AS; Klatte T
    J Urol; 2013 Dec; 190(6):1999-2004. PubMed ID: 23831313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, and multiphasic renal tomography findings in histological subtypes of renal cell carcinoma.
    Keskin S; Keskin Z; Taskapu HH; Kalkan H; Kaynar M; Poyraz N; Toy H
    BMC Urol; 2014 Nov; 14():95. PubMed ID: 25427576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
    Tanaka N; Mizuno R; Yasumizu Y; Ito K; Shirotake S; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
    Urol Oncol; 2017 Feb; 35(2):39.e19-39.e28. PubMed ID: 27825515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hypertension on preoperative neutrophil-lymphocyte ratio evaluation of prognosis of renal cell carcinoma.
    Sun J; Ning H; Sun J; Qu X
    Urol Oncol; 2016 May; 34(5):239.e9-15. PubMed ID: 26803433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma.
    Sejima T; Iwamoto H; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Takenaka A
    Urol Oncol; 2013 Oct; 31(7):1343-9. PubMed ID: 22153754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
    Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
    Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma.
    Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Hamano I; Fujita N; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
    Int J Urol; 2019 Oct; 26(10):992-998. PubMed ID: 31342557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative Neutrophil to Lymphocyte Ratio as a Prognostic Factor in Patients with Non-metastatic Renal Cell Carcinoma.
    Wen RM; Zhang YJ; Ma S; Xu YL; Chen YS; Li HL; Bai J; Zheng JN
    Asian Pac J Cancer Prev; 2015; 16(9):3703-8. PubMed ID: 25987025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma.
    Yamamoto Y; Matsuyama H; Matsumoto H; Sakano S; Fuji N; Oba K; Yamamoto M; Kamiryo Y; Hiragino T; Nagao K; Takai K; Aoki A
    Jpn J Clin Oncol; 2020 Feb; 50(2):214-220. PubMed ID: 31755525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of hemoglobin-to-red cell distribution width ratio in patients with metastatic renal cancer.
    Yılmaz H; Yılmaz A; Demirağ G
    Future Oncol; 2021 Oct; 17(29):3853-3864. PubMed ID: 34382414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.